NXTC - NextCure Inc

NXTC - NextCure Inc

https://www.nextcure.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference - NextCure ( NASDAQ:NXTC )

Benzinga • 1 week, 4 days ago • score: 0.08

BELTSVILLE, Md., Sept. 04, 2025 ( GLOBE NEWSWIRE ) -- NextCure, Inc. NXTC, a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will participate in a fireside chat at the H.C.

NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire • 1 week, 4 days ago • score: 0.09

BELTSVILLE, Md., Sept. 04, 2025 ( GLOBE NEWSWIRE ) -- NextCure, Inc. ( Nasdaq: NXTC ) , a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will participate in a fireside ...

NextCure ( NXTC ) Q2 Loss Widens 71%

Motley Fool • 1 month, 1 week ago • score: 0.25

NextCure ( NASDAQ:NXTC ) , a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates and immune medicines for cancer and other diseases, released its second quarter results on August 7, 2025.

Nextcure Stock Skyrockets Nearly 45% In After-Hours Trading After Sharing Preclinical Data For Brittle Bone Disease - NextCure ( NASDAQ:NXTC )

Benzinga • 1 month, 3 weeks ago • score: 0.08

NextCure Inc. NXTC stock surged by 44.87% to $7.62 in after-hours trading on Thursday. What Happened: The surge in NextCure's stock value came after the company presented new preclinical data for NC605, a potential treatment for brittle bone disease.

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

GlobeNewswire • 2 months, 4 weeks ago • score: 0.16

BELTSVILLE, Md. and SHANGHAI, June 16, 2025 ( GLOBE NEWSWIRE ) -- NextCure, Inc. ( Nasdaq: NXTC ) , a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, and Simcere Zaiming, an oncology-focused ...

NextCure to Present at 24th Annual Needham Virtual Healthcare Conference - NextCure ( NASDAQ:NXTC )

Benzinga • 5 months, 1 week ago • score: 0.13

BELTSVILLE, Md., April 04, 2025 ( GLOBE NEWSWIRE ) -- NextCure, Inc. NXTC, a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will present at the 24th Annual Needham Virtual ...

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 ( B7-H4 ADC ) as Therapeutic for Treating Multiple Cancers - NextCure ( NASDAQ:NXTC )

Benzinga • 8 months ago • score: 0.17

BELTSVILLE, Md., Jan. 10, 2025 ( GLOBE NEWSWIRE ) -- NextCure, Inc.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

NextCure, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of novel immunomedicines to treat cancer and other diseases related to the immune system by restoring normal immune function. The company is headquartered in Beltsville, Maryland.

52W High

$19.20

52W Low

$2.69

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.28

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

0.51

EV/Revenue (<3 favorable)

1.62

P/S (TTM) (<3 favorable)

9.52

P/B (<3 favorable)

0.41

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

14.79%

Institutions (25–75% balanced)

32.58%

Shares Outstanding

2,676,100

Float

1,878,800

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

-54,199,000

EPS (TTM)

-25.97

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-1.06%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-1.00

Momentum

Bearish momentum

Value

0.0498

Previous

0.0263

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025